Advertisement

  • Pembrolizumab Shows Further Promise for Melanoma

    In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.

    by Brad Jones

  • Forward Look

    Tackling Drug Resistance

    Researchers are studing new ways to keep treatments working longer.

    by Stephen Ornes

  • Survivor Profile

    Living in the Here and Now

    A metastatic melanoma survivor is hopeful but realistic as new treatments become available.

    by Jenny Song

  • Forward Look

    Cancer Immunotherapies Continue to Make Headway

    Drugs that harness the power of the immune system gain new approvals.

    by Alexandra Goho

  • Survivor Profile

    Knowing Her Options

    When Christina McEvoy was diagnosed with stage IV melanoma, she took the reins of her care, traveling more than 600 miles for treatment and returning home to help other melanoma survivors.

    by Melissa Davlin

  • First Person

    Keeping Sight of Hope

    A survivor keeps an eye on what's ahead after a rare cancer diagnosis.

    by Sue Russell

Advertisement
Advertisement

From the AACR

  • Making Mammography Better

    A study investigates whether artificial intelligence can reduce false-positive mammograms.

  • New FDA Approvals

    Three new cancer treatments have been approved by the U.S. Food and Drug Administration.

  • Nobel Prize for Immunotherapy

    James P. Allison, PhD, a Fellow of the AACR Academy, won the 2018 Nobel Prize in Physiology or Medicine for his pioneering work in cancer immunotherapy.

Advertisement

Video

Janet Freeman-Daily: On Lung Cancer and Blame

Advertisement

social media

donate to the AACR